Clinical features and outcome of neuropsychiatric lupus in Chinese: analysis of 240 hospitalized patients

Abstract

Neuropsychiatric (NP) events are severe manifestations of systemic lupus erythematosus (SLE) and relate to poor outcome. The aims of this study are to investigate the NP manifestations of SLE and to identify the predictive factors for clinical outcome. There was a retrospective review of 240 hospital patients with primary NP events of SLE (NPSLE) from 1990 to 2004. Neuropsychiatric manifestations, SLE disease activity index (SLEDAI) score, System lupus International Collaborating Clinic/American College of Rheumatology Damage Index (SLICC/ACR-DI) score, magnetic resonance imaging (MRI) findings, treatment and mortality rate were included for analysis. From this group of patients, 15 NP syndromes were identified. The most frequent manifestation was headache, followed by seizure. The mean SLEDAI and SLICC/ACR-DI scores were 19.9 ± 6.9 and 3.5 ± 1.6, respectively. Abnormal MRI features were found in 67% (61/91) patients. At least one intrathecal (IT) injection of methotrexate (MTX) plus dexamethasone (DXM) was administered to 109 (45.4%) patients. High dose (1 g) intravenous methylprednisolone pulse therapy (IVMP) was administered to 167 (69.5%) patients. Multifactor analysis revealed that high SLICC/ACR-DI scores and sets of concurrent NP symptoms were independently associated with poor outcome, whereas pulse IVMP and IT injection of MTX plus DXM were protective factors against poor outcome. From our data, NPSLE is heterogeneous and is usually associated with high disease activity and organ damage scores. High SLICC/ACR-DI score and having more than two sets of NP symptoms are the predictors for poor outcome, whereas pulse IVMP and IT injection of MTX plus DXM can improve the prognosis. Lupus (2008) 17, 93—99.

Keywords

magnetic resonance imaging neuropsychiatric outcome systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Hanly JG , Neuropsychiatric lupus. Curr Rheumatol Rep 2001; 3: 205—212.

Jennekens FG , Kater L. The central nervous systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford) 2002; 41: 605—618.

Hermosillo RD , Brey RL Neuropsychiatric involvement in systemic lupus erythematosus. Curr Rheumatol Rep 2002; 4: 337—344.

Ward MM , Pyun E. , Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med 1996; 156: 1337—1344.

Rubin LA , Urowitz MB , Gladman DD Mortality in systemic lupus erythematosus: the bimodal pattern revisited . Q J Med 1985; 55: 87—98.

Gibsin T. , Myers AR Nervous system involvement in systemic lupus erythematosus. Ann Rheum Dis 1975; 35: 398—406.

Zhang X. , Dong Y. , Tang F. , Li H. , Zhang F. Central nervous system involvement in systemic lupus erythematosus in a hospital-based study of 171 cases. The possible therapeutic role of intrathecal therapy. J Clin Rheumatol 1999; 6: 314—319.

Abreu MR , Jakosky A. , Folgerini M. , Brenol JC , Xavier RM , Kapczinsky F. Neuropsychiatric systemic lupus erythematosus: correlation of brain MR imaging, CT, and SPECT. Clin Imaging 2005 ; 29: 215—221.

Ainiala H. , Dastidar P. , Loukkola J. et al. Cerebral MRI abnormalities and their association with neuropsychiatric manifestations in SLE: a population-based study. Scand J Rheumatol 2005; 34: 376—382.

10.

Walecki J. , Sierakowski S. , Lewszuk A. , Sulik A. , Tarasow E. , LEbkowska U. MR in neurological of connective tissue disease. Med Sci Moni 2002; 8: MT105—111.

11.

Jennings JE , Sundgren PC , Attwood J. , McCune J. , Maly P. Value of MRI of the brain in patients with systemic lupus erythematosus and neurologic disturbance . Neuroradiology 2004; 46: 15—21.

12.

ACR Ad Hoc Committee on Neuropsychiatric lupus. The American College of Rheumatology and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599—608.

13.

Hochberg MC Updating the American Collage of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter] . Arthritis Rheum 1997; 40: 1725.

14.

Bonbardier C. , Gladman DD , Urowitz MB , Caron D. , Chang CH Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630—640.

15.

Gladman D. , Ginzler E. , Goldsmith C. et al. The development and initial validation of the systemic lupus international collaborating clinics/America college if rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363—369.

16.

Neuwelt CM , Lacks S. , Kaye BR , Ellman JB , Borenstein DG Role of intravenous cyclophosphamide in the systemic lupus erythematosus . Am J Med 1995; 98: 32—41.

17.

Zhou HQ , Leng XM , Zhang FC Neuropsychiatric manifestations in systemic lupus erythematosus and the treatment of intrathecal methotrexate plus dexamethasone. Zhonghua Yi Xue Za Zhi 2006; 86: 771—774.

18.

Karassa FB , Ioannidis JPA , Touloumi G. , Boki KA , Moutsopoulos HM Risk factors for central nervous system involvement in systemic lupus erythematosus . Q J Med 2000; 93: 169—174.

19.

Brey RL , Holliday SL , Saklad AR et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002; 58: 1214—1220.

20.

Ainiala H. , Loukkola J. , Peltola J. , Korpela M. , Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus . Neurology 2001; 57: 496—500.

21.

Sanna G. , Bertolaccini ML , Cuadrado MJ , Khamashta MA , Hughes GRV. Neuropsychiatric manifestations in systemic lupus erythematosus: Prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30: 985—992.

22.

Hanly JG , McCurdy G. , Fougere L. , Douglas J. , Thompson K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 2005 ; 32: 1459—1456.

23.

Mok CC , Lau CS , Wong RWS. Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 766—771.

24.

Winfield JB , Brunner CM , Koffler D. Serologic studies in patients with systemic lupus erythematosus and central nervous system dysfunction . Arthritis Rheum 1978; 21: 289—294.

25.

Shimojima Y. , Matsuda M. , Gono T. , Ishii W. , Ikeda S. Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus . Clin Rheumatol 2005, 24: 469—475.

26.

Sibbitt JWL , Sibbitt RR , Griffey RH , Eckel C. , Bankhurst AD Magnetic resonance and computed tomographic imaging in the evaluation of acute neuropsychiatric disease in systemic lupus erythematosus. Ann Rheum Dis 1989; l48: 1014—1022.

27.

Zimmerman RD , Fleming CA , Lee BC , Saint-Louis LA , Deck MD Periventricular hyperintensities as seen by magnetic resonance: prevalence and significance . Am J Neuroradiol 1986; 146: 443—450.

28.

Jennekens FG , Kater L. The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology (Oxford) 2002 ; 41: 619—630.

29.

Ramos PC , Mendez MJ , Ames PR , Khamashta MA , Hughes GR Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol 1996 ; 14: 295—299.

30.

Schroeder JO , Euler HH Treatment combining plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Adv Exp Med Bio 1989; 260: 203—213.

31.

Sherer Y. , Levy Y. , Langevitz P. , Lorber M. , Fabrizzi F. , Shoenfeld Y. Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol 1999; 18: 170—173.

32.

Barile L. , Lavalle C. Traverse myelitis in systemic lupus erythematosus — the effect of IV pluse methylprednisolone and cyclophosphamide. J Rheumatol 1992; 19: 370—372.

33.

Grisanti M. , Nader A. , Cacciuttolo R. Central nervous system involvement due to systemic lupus erythematosus/antiphospholipid syndrome: successful treatment with mycophenolate mofetil [abstract]. Lupus 2001; 10: s31.

34.

Saito K. , Nawata M. , Nakayamada S. , Tokunaga M. , Tsukada J. , Tanaka Y. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus 2003; 12: 798—800.

35.

Fabris BL , Ariza-Andraca R. , Olguín-Ortega L. et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 620—625.

36.

Karassa FB , Ioannidis JP , Boki KA et al. Predictor of clinical outcome and radiologic progression in patients with neuropsychiatic manifestations of systemic lupus erythematosus. Am J Med 2000; 109: 628—634.

37.

Jonsen A. , Bengtsson AA , Nived O. , Ryberg B. , Sturfelt G. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbility but low mortality. Rheumatology 2002; 41: 1308—1312.

38.

Zhang F. , Dong Y. , Zhao Y. , Ling H. The diagnosis and treatment of 72 patients with central nervous system involvement of systemic lupus erythematosus. Beijing Med J 1994; 16: 277—280.

39.

Valesini G. , Priori R. , Francia A. et al. Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate. Springer Semin Immunopathol 1994; 16: 313—321.